Valproic Acid Capsule, Liquid Filled
Product Images NDC 70518-0079

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Valproic Acid (NDC 70518-0079). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

Label of Valproic Acid 250 mg capsule, liquid filled, with a quantity of 30 capsules. The label includes the NDC number 70518-0079-00, repackaged by RemedyRepack Inc., Indiana, PA, and manufactured by Bionpharma Inc., Princeton, NJ. Storage instructions and a QR code are also present.*

FDA Label Image

Mm2 (Valproic Acid 250mg 70518 0079 01)

Label for Valproic Acid 250 mg capsules, liquid filled, with a quantity of 100. The label includes the proprietary name, strength, dosage form, and indicates the product is Rx only. It is repackaged by RemedyRepack Inc. and the original manufacturer is Bionpharma Inc., Princeton, NJ. Storage instructions and a barcode are also visible.*

FDA Label Image

Mm3 (Valproic Acid 250mg 70518 0079 02)

Label for Valproic Acid 250 mg capsule, liquid filled, oral use. The label indicates a quantity of 1 capsule. It shows the NDC number 70518-0079-02, manufacturer as Bionpharma Inc., and repackager RemedyRepack Inc. Important instructions include storing at 20-25°C with permitted excursions, and a note to see package insert for directions.*

FDA Label Image

Undefined (Image 00001)

Chemical structure of Valproic Acid, showing its molecular formula with carbon (CH3, CH2, CH), oxygen (O), and hydrogen atoms arranged to depict the compound's structural formula.*

FDA Label Image

Undefined (Image 00002)

A line graph comparing percentage reduction in CPS rate between Depakote and placebo across the percentage of patients. The vertical axis shows reduction in CPS rate from -100% to 100%, with labels indicating improvement, no change, and worsening. The horizontal axis shows percentage of patients from 0 to 100. Two lines represent Depakote (solid) and placebo (dashed), with Depakote showing greater improvement than placebo overall.*

FDA Label Image

Undefined (Image 00003)

A line graph depicting the percentage reduction in CPS Rate on the vertical axis versus percentage of patients on the horizontal axis. Two lines represent high dose (solid) and low dose (dashed) groups. The graph shows changes from worsening to improvement, crossing the no change baseline.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.